CSIMarket
 
Alector Inc   (ALEC)
Other Ticker:  
 
 
Price: $6.0000 $-0.12 -1.961%
Day's High: $6.21 Week Perf: 1.87 %
Day's Low: $ 5.82 30 Day Perf: -7.55 %
Volume (M): 706 52 Wk High: $ 9.07
Volume (M$): $ 4,235 52 Wk Avg: $6.48
Open: $6.21 52 Wk Low: $3.66



 Market Capitalization (Millions $) 504
 Shares Outstanding (Millions) 84
 Employees 155
 Revenues (TTM) (Millions $) 96
 Net Income (TTM) (Millions $) -141
 Cash Flow (TTM) (Millions $) -82
 Capital Exp. (TTM) (Millions $) 3

Alector Inc
Alector Inc.
is a clinical-stage biotechnology company focused on the development of immunotherapy treatments for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and various forms of dementia.
The company was founded in 2013 and is headquartered in South San Francisco, California.
Alector's approach to treating neurodegenerative diseases is based on the principles of immunology and genetics.
The company develops drugs that target the immune system, specifically the immune cells in the brain, to help clear toxic proteins that are linked to neurodegeneration.
These drugs are designed to activate the body's own immune system to fight disease and promote healing.
The company's pipeline includes a number of potential treatments for Alzheimer's disease, including AL001, a drug designed to target the progranulin pathway, and AL002, which targets a specific form of Tau protein.
Alector is also developing drugs for Parkinson's disease and frontotemporal dementia.
Alector has formed partnerships with several pharmaceutical companies to accelerate the development of its drugs, including AbbVie, GlaxoSmithKline, and Eli Lilly.
The company has also raised significant funding, including $133 million in an initial public offering in 2019.
Overall, Alector is focused on developing new treatments for debilitating and currently untreatable neurological conditions, with the potential to improve the lives of millions of people worldwide.


   Company Address: 131 Oyster Point Blvd South San Francisco 94080 CA
   Company Phone Number: 231-5660   Stock Exchange / Ticker: NASDAQ ALEC
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Exploring the Future of Alzheimer's Treatment: A Look into Alector's PROGRESS-AD Clinical Trial

Published Thu, Feb 8 2024 12:00 PM UTC

In a significant development for the field of Alzheimer's disease research, Alector recently announced the dosing of its first patient in the PROGRESS-AD Phase 2 clinical trial. Conducted in partnership with GSK, this innovative trial aims to evaluate the efficacy and safety of AL101/GSK4527226 in patients with early-stage Alzheimer's disease. With an anticipated global enro...

Partnership

FDA Grants Breakthrough Therapy Status to Alector Inc's Latozinemab for FTD-GRN, Amid Fluctuating Revenue Trends.

Published Wed, Feb 7 2024 12:00 PM UTC

In a significant development in dementia therapy, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Latozinemab for the treatment of Frontotemporal Dementia due to a Progranulin Gene Mutation (FTD-GRN). This is the most advanced progranulin-elevating drug presently under development for this form of dementia and represents a remarkab...

Financing Agreement

South San Francisco, Calif, Jan 19, 2024 - In an impressive move for the field of immuno-neurology, Alector, Inc (Nasdaq: ALEC), a leading clinical-stage biotechnology company, has successfully completed its underwritten public offering of shares of its common stock The offering saw Alector sell an impressive 10,869,566 shares of its common stock, signifying the company's steadfast commitment to advancing breakthrough treatments in this innovative sector

Published Fri, Jan 19 2024 2:21 PM UTC

South San Francisco, Calif., Jan. 19, 2024 - In an impressive move for the field of immuno-neurology, Alector, Inc. (Nasdaq: ALEC), a leading clinical-stage biotechnology company, has successfully completed its underwritten public offering of shares of its common stock. The offering saw Alector sell an impressive 10,869,566 shares of its common stock, signifying the company'...

Shares

Alector Ushers in New Era of Neuroscience Research with Successful Pricing of Public Offering

Published Wed, Jan 17 2024 1:54 PM UTC

Alector Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 - Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company specializing in immuno-neurology, disclosed today the pricing of an underwritten public offering of 10,869,566 shares of its common stock. The offering is set to generate total gross proceeds of $75...

Shares

Alector's Immuno-Neurology Advances Fuels Excitement as Proposed Public Stock Offering Looms

Published Tue, Jan 16 2024 9:01 PM UTC



SOUTH SAN FRANCISCO, Calif. - Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company leading the way in immuno-neurology research, disclosed its plan today to offer shares of its common stock to the public. The proposed underwritten public offering, subject to market conditions and other variables, aims to enable Alector to raise capital for its groun...






 

Alector Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com